Where it comes from
- Made in
- D cells of the gut above all; some in the hypothalamus
- Sent out by
- Nutrients, especially fat and protein, in the small intestine
- Acts on
- Pancreatic islets
- Pituitary
- Gut
What it does
- The somatostatin that actually rises in blood after a meal; somatostatin-14 barely moves 2
- More potent than somatostatin-14 at suppressing insulin, and its preference for SSTR5, the receptor the beta cell carries, is why 3
- Longer-lived in blood, so it is the form that can act at a distance rather than only on its neighbours
In medicine
- Covered by the same analogues: no approved medicine distinguishes the two forms, and pasireotide was designed for breadth across the receptors rather than for either one 3
- Measured in research only. Telling it from somatostatin-14 needs a form-specific assay, which is why most published “somatostatin” levels are a mixture
Beyond the body’s own use
- Not studied as a treatment in its own right. Its claim to attention is physiological: when antibodies were used to neutralise it alone in baboons, insulin release after a meal rose, which makes it a genuine after-meal brake rather than a processing by-product 1
- What is not known is whether the same holds in people. Nobody has blocked somatostatin-28 selectively in a person, so its share of the normal control of insulin is an inference from one primate study 1
Sources
- Ensinck et al., Endogenous somatostatin-28 modulates postprandial insulin secretion, Journal of Clinical Investigation 1997
- D’Alessio et al., Fasting and postprandial somatostatin-28 and somatostatin-14 in type 2 diabetes, Diabetes 1990
- Günther et al., Somatostatin receptors: structure, function, ligands and new nomenclature, Pharmacological Reviews 2018
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.